Format

Send to

Choose Destination
Eur J Pharmacol. 2014 Feb 5;724:1-8. doi: 10.1016/j.ejphar.2013.12.018. Epub 2013 Dec 18.

Cardiac SERCA2A/B: therapeutic targets for heart failure.

Author information

1
College of Medicine, AlFaisal University, Riyadh, Saudi Arabia.
2
Cardiovascular Research Program, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia; San Diego State University, Department of Biology, 5500 Campanile Drive, San Diego, CA 92182, USA. Electronic address: cpoizat99@kfshrc.edu.sa.

Abstract

Calcium (Ca(2+)) recycling is key for effective relaxation of the cardiac muscle. Failure to properly recycle calcium through the sarcoplasmic reticulum (SR) results in severe impairment of myocardial relaxation and consequently alteration of the "beat-to-beat" heart rhythm and contractile function. The Sarco(Endo)plasmic reticulum Ca(2+) ATPase (SERCA) is instrumental for recycling cytosolic Ca(2+) into the lumen of the SR. Among the many SERCA isoforms identified so far, SERCA2a is restricted to slow-twitch skeletal and cardiac muscle, while SERCA2b is ubiquitously expressed. SERCA2a/b expression and activity are altered in major heart diseases such as ischemic heart disease, cardiomyopathies and congestive heart failure. Restoring adequate SERCA2a/b expression by pharmacological action or gene delivery has emerged as a new approach for the treatment of heart failure. In this review we describe the drugs adopted in clinical practice that activate SERCA2a/b function as well as new promising therapeutic tools using SERCA2 viral gene delivery to improve cardiac function and treat heart failure.

KEYWORDS:

Calcium; Heart failure; SERCA2a/b; Sarco/endoplasmic reticulum Ca(2+)-ATPase

PMID:
24361307
DOI:
10.1016/j.ejphar.2013.12.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center